(Q40658274)

22 September 2017

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder (English)

1 reference

22 September 2017

phase II clinical trial

0 references

author name string

M Khorsand

1

1 reference

22 September 2017

J Lange

2

1 reference

22 September 2017

L Feun

3

1 reference

22 September 2017

N J Clendeninn

4

1 reference

22 September 2017

M Collier

5

1 reference

22 September 2017

G Wilding

6

1 reference

22 September 2017

1 January 1997

1 reference

Investigational New Drugs

22 September 2017

1 reference

22 September 2017

15

1 reference

22 September 2017

157-163

1 reference

22 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1005860806635

22 September 2017

0 references

cites work

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

1 reference

12 December 2020

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

12 December 2020

Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract

1 reference

12 December 2020

Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake.

1 reference

12 December 2020

Cancer statistics, 1995.

1 reference

12 December 2020

Chemotherapy of urothelial tract tumors

1 reference

12 December 2020

Two different species of dihydrofolate reductase in mammalian cells differentially resistant to amethopterin and methasquin

1 reference

12 December 2020

A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study

1 reference

12 December 2020

Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase

1 reference

12 December 2020

Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells.

1 reference

12 December 2020

Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells

1 reference

12 December 2020

Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo

1 reference

12 December 2020

Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies

1 reference

12 December 2020

Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells

1 reference

12 December 2020

Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells

1 reference

12 December 2020

Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world

1 reference

12 December 2020

Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells

1 reference

12 December 2020

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells

1 reference

12 December 2020

Oral piritrexim, an effective treatment for metastatic urothelial cancer

1 reference

12 December 2020

A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer

1 reference

12 December 2020

Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial

1 reference

12 December 2020

Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma

1 reference

12 December 2020

Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases

1 reference

12 December 2020

Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells

1 reference

12 December 2020

Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma

1 reference

12 December 2020

Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate

1 reference

12 December 2020

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration

1 reference

12 December 2020

2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii

1 reference

12 December 2020

A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma

1 reference

12 December 2020

Methotrexate Polyglutamates in Cultured Human Cells

1 reference

12 December 2020

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

1 reference

12 December 2020

Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy?

1 reference

12 December 2020

Initial clinical studies of piritrexim.

1 reference

12 December 2020

Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers

1 reference

12 December 2020

Hybridization of hamster cells with high and low folate reductase activity

1 reference

12 December 2020

Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1005860806635

1 reference

Dimensions Publication ID

22 September 2017

0 references

1 reference